Anaplastic large cell lymphoma is a rare disease associated with breast implants. We present the case of a woman who had had breast augmentation and multiple revisions over a period of 13 years and presented with recurrent fluid collections. The cause was determined to be anaplastic large cell lymphoma, which required removal of the implants, capsulectomy, and evaluation by a medical oncologist. The patient was not found to have metastatic disease on imaging studies. Breast implant-associated anaplastic large cell lymphoma is a poorly understood disease entity, and optimal treatment is unclear.
B
reast implant-associated anaplastic lymphoma kinase (ALK)-negative large cell lymphoma (BIA-ALCL) is a rare clinical entity, with fewer than 400 reported cases in the literature, most of which are case reports. It was fi rst described in 1997 (1) and has a suspected incidence of 0.3% per 100,000 women per year (2) . Th is may be a gross underestimation, given the number of breast augmentation and reconstructive procedures performed worldwide, and could refl ect the diffi culty in establishing a diagnosis. Th is case report describes a 60-year-old woman with BIA-ALCL.
CASE STUDY
A 60-year-old white woman with no signifi cant past medical history presented to her plastic surgeon with a grossly distorted, swollen, and enlarged left breast without evidence of a mass (Figure 1 ). Th ere was no history of trauma or systemic symptoms. She previously had breast augmentation with multiple revisions; the fi rst procedure took place when she was 43 years old. Th e procedure used polyurethane implants in the subglandular location. Th e patient subsequently had three further revisions of her augmentation secondary to recurrent fl uid accumulation on the left breast.
At age 59, the patient began to have increasing fi rmness and tenderness of the left breast, which was associated with yet another fl uid collection requiring implant exchange. Th e plastic surgeon performed further workup for this fl uid accumulation prior to performing another revision of her augmentation. A diagnostic mammogram and ultrasound revealed only a small amount of fl uid around the left implant in the 12 o'clock position. A computed tomography scan of the chest without contrast revealed an asymmetric undulating contour of the left breast prosthesis with mass eff ect from fl uid of variable densities, with no evidence of implant rupture, but an infl ammatory, infectious, or lymphoma etiology could not be ruled out. A discussion ensued with the patient concerning these fi ndings; ultimately, she elected to have her implants removed without replacement until the etiology could be identifi ed. Th e patient underwent bilateral implant removal with capsulectomies, which was uneventful on the right side. Fluid was evacuated on the left side and revealed a capsule that was thickened with a plaque-like mass and mucoid material associated with capsule posteriorly. Th is could not be entirely resected, as it adhered to the underlying chest wall beneath the pectoralis major muscle. Th e remaining mass was debrided with a scratch pad, drains were placed, and the wounds were closed. Th e patient healed well postoperatively.
Final pathology of the capsules revealed atypical infi ltrate consistent with ALK-negative ALCL associated with a breast implant. Hematoxylin and eosin studies (Figure 2a and has an excellent prognosis in comparison to mass-forming disease or systemic ALK-negative ALCL, which may have more aggressive courses and worse prognoses (5).
To date, there is no consensus on the implant substance contributing to disease, but more cases have been reported with textured versus smooth implants. Th is may indicate that the infl ammatory response is causative in disease formation, but that hypothesis has not been proven.
Th e diff erential diagnosis for BIA-ALCL is broad and includes dissemination from systemic ALCL, classical Hodgkin lymphoma, other primary breast lymphoma, misinterpretation of triple-negative breast carcinoma, seroma formation from trauma, and double capsule formation (2, 4, 5) . Treatment options to date consist of surgical therapy including implant removal and capsulectomy versus surgical and systemic therapy with or without radiation, typically indicated if the patient has classic B symptoms (2, 4, 6) . Th e FDA recommends reporting all confi rmed cases to improve the understanding of this rare disease.
performed; immunohistochemical analysis was positive for CD4, CD30 (Figure 2b) , and CD45 but negative for CD2, CD3, CD5, CD20, TIA, CD7, PAX5, and pancytokeratin with an MIB-1 of 80% (Figure 2c) . Th e patient was sent to a medical oncologist for discussion of treatment options. A positron emission tomography-computed tomography (PET/CT) scan was ordered and was negative for metastatic disease. A follow-up PET/CT scan for surveillance is scheduled.
DISCUSSION
In 2016, about 290,000 women in the United States had breast augmentation using implants; 109,000 of these women received them for reconstruction after breast cancer (3) . Th e Food and Drug Administration (FDA) released a statement in early 2017 concerning a rare cancer, ALCL, that has been linked to breast implants and is associated with nine deaths. Th e FDA has received 359 reports of BIA-ALCL and only recently released its statement because of advancements in the description of the disease and treatment recommendations as a result of numerous case reports in the literature.
A systematic review and structured expert panel was organized by Kim et al to advise clinicians when BIA-ALCL may be suspected. Th e panel agreed that there was an association between implants and ALK-negative ALCL and that a delayed or recurrent seroma beyond 6 months should be investigated with aspiration and cytologic analysis or fl ow cytometry to rule out infection and lymphoma (4) .
In general, BIA-ALCL typically manifests as a seroma or fl uid collection but may present with a discrete mass originating from the fi brous capsule around the implant as opposed to the breast parenchyma. Microscopically, the tumor cells are present in the seroma fl uid or on the inner surface of the fi brous capsule and may form sheets along the capsule in mass-forming disease (5). Seroma-forming disease usually follows an indolent clinical course 
